Federal Register: December 31, 2002 (Volume 67, Number 251)
DOCID: FR Doc 02-33023
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NOTICE: NOTICES
ACTION: Meetings:
SUBJECT CATEGORY:
National Institute of Allergy And Infectious Diseases; Notice of Closed Meeting
DOCUMENT SUMMARY:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP).
Date: January 1617, 2003.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Anthony Macaluso, PhD, Scientific Review
Administrator, Scientific Review Program, National Institute of
Allergy and, Infectious Diseases, DEA/NIH/DHHS, 6700B Rockledge
Drive, MSC 7616, Room 2153, Bethesda, MD 20892, 3014020643,
amacaluso@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: December 18, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0233023 Filed 123002; 8:45 am]
BILLING CODE 414001M
SUMMARY:
National Institute of Allergy and Infectious Diseases,
DOCUMENT BODY 2:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP).
Date: January 1617, 2003.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Anthony Macaluso, PhD, Scientific Review
Administrator, Scientific Review Program, National Institute of
Allergy and, Infectious Diseases, DEA/NIH/DHHS, 6700B Rockledge
Drive, MSC 7616, Room 2153, Bethesda, MD 20892, 3014020643,
amacaluso@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: December 18, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0233023 Filed 123002; 8:45 am]
BILLING CODE 414001M